|
|
Antimicrob Agents Chemother. 1993 September; 37(9): 1746–1748. | PMCID: PMC188064 |
In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. A Agacfidan, J Moncada, and J Schachter Department of Microbiology, Istanbul Faculty of Medicine, Turkey. Abstract The in vitro susceptibilities of 49 strains of Chlamydia trachomatis and 3 strains of Chlamydia pneumoniae to azithromycin and tetracycline or doxycycline were determined. The MIC of azithromycin ranged from < or = 0.06 to 1.0 micrograms/ml, the MIC of tetracycline ranged from 0.03 to 0.12 micrograms/ml, and the MIC of doxycycline ranged from 0.015 to 0.06 micrograms/ml against C. trachomatis. The MIC ranges for C. pneumoniae were 0.12 to 0.25 micrograms/ml for azithromycin and 0.06 to 0.12 micrograms/ml for tetracycline. All minimal chlamydicidal concentrations were either equal to the MIC or one or two dilutions higher. No strains resistant to these antibiotics were detected. In vitro activity shows that azithromycin is highly active against C. trachomatis and C. pneumoniae. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (573K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. These references are in PubMed. This may not be the complete list of references from this article. - Børsum T, Dannevig L, Størvold G, Melby K. Chlamydia trachomatis: in vitro susceptibility of genital and ocular isolates to some quinolones, amoxicillin and azithromycin. Chemotherapy. 1990;36(6):407–415. [PubMed]
- Chirgwin K, Roblin PM, Hammerschlag MR. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob Agents Chemother. 1989 Sep;33(9):1634–1635. [PubMed]
- Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990 Jan;25 Suppl A:73–82. [PubMed]
- Grayston JT. Chlamydia pneumoniae, strain TWAR. Chest. 1989 Mar;95(3):664–669. [PubMed]
- Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Jul;36(7):1573–1574. [PubMed]
- Linnemann CC, Jr, Heaton CL, Ritchey M. Treatment of Chlamydia trachomatis infections: comparison of 1- and 2-g doses of erythromycin daily for seven days. Sex Transm Dis. 1987 Apr–Jun;14(2):102–106. [PubMed]
- Martin DH, Mroczkowski TF, Dalu ZA, McCarty J, Jones RB, Hopkins SJ, Johnson RB. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N Engl J Med. 1992 Sep 24;327(13):921–925. [PubMed]
- Mourad A, Sweet RL, Sugg N, Schachter J. Relative resistance to erythromycin in Chlamydia trachomatis. Antimicrob Agents Chemother. 1980 Nov;18(5):696–698. [PubMed]
- Sanders LL, Jr, Harrison HR, Washington AE. Treatment of sexually transmitted chlamydial infections. JAMA. 1986 Apr 4;255(13):1750–1756. [PubMed]
- Schachter J, Hanna L, Hill EC, Massad S, Sheppard CW, Conte JE, Jr, Cohen SN, Meyer KF. Are chlamydial infections the most prevalent venereal disease? JAMA. 1975 Mar 24;231(12):1252–1255. [PubMed]
- Schönwald S, Skerk V, Petricevic I, Car V, Majerus-Misic L, Gunjaca M. Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):877–880. [PubMed]
- Walsh M, Kappus EW, Quinn TC. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. Antimicrob Agents Chemother. 1987 May;31(5):811–812. [PubMed]
- Welsh LE, Gaydos CA, Quinn TC. In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Feb;36(2):291–294. [PubMed]
|
This article has been